Concepedia

Publication | Open Access

High dose osimertinib in patients with advanced stage EGFR exon 20 mutation-positive NSCLC: Results from the phase 2 multicenter POSITION20 trial

DOIFull Paper Access

60

Citations

33

References

2022

Year

Fenneke Zwierenga, Bianca van Veggel, Lizza Hendriks, T. Jeroen N. Hiltermann, Birgitta I. Hiddinga, Lucie B.M. Hijmering Kappelle, Arja ter Elst, Sayed M.S. Hashemi, Anne‐Marie C. Dingemans, Cor van der Leest,
Lung Cancer

Abstract

The POSITION20 study showed modest antitumor activity in patients with EGFRex20 + NSCLC treated with 160 mg osimertinib, with a confirmed ORR of 28% and acceptable toxicity.

References

YearCitations

Page 1